NCT05643170View on ClinicalTrials.gov

An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia

PHASE3TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

November 8, 2022

Primary Completion Date

March 1, 2023

Study Completion Date

March 8, 2023

Conditions
Schizophrenia
Interventions
DRUG

Xanomeline and Trospium Chloride Capsules

KarXT 50 mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID

Trial Locations (5)

29732

OnSite Clinical Solutions, LLC, Rock Hill

30318

Advanced Discovery Research, LLC, Atlanta

40203

Seven Counties Services, Inc., Louisville

43205

Mid Ohio Behavioral Health, Columbus

84770

Integrated Clinical Research, St. George

Sponsors
All Listed Sponsors
lead

Karuna Therapeutics

INDUSTRY

NCT05643170 - An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia | Biotech Hunter | Biotech Hunter